Shanghai Pharmaceuticals Holding
Market Cap
HK$55.9b
Last Updated
2020/02/26 13:07 UTC
Data Sources
Company Financials +
Executive Summary
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People’s Republic of China.
Rewards
Risk Analysis
Snowflake Analysis
Good value average dividend payer.
Similar Companies
Share Price & News
How has Shanghai Pharmaceuticals Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2607 has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-5.2%
2607
-4.6%
HK Healthcare
-3.3%
HK Market
1 Year Return
-17.7%
2607
-27.4%
HK Healthcare
-9.6%
HK Market
Return vs Industry: 2607 exceeded the Hong Kong Healthcare industry which returned -26.9% over the past year.
Return vs Market: 2607 underperformed the Hong Kong Market which returned -9.8% over the past year.
Shareholder returns
| 2607 | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.2% | -4.6% | -3.3% |
| 30 Day | -2.0% | -7.0% | -3.8% |
| 90 Day | 6.1% | -5.8% | -0.2% |
| 1 Year | -15.2%-17.7% | -25.7%-27.4% | -6.3%-9.6% |
| 3 Year | -22.9%-28.2% | -33.3%-37.2% | 11.2%-0.05% |
| 5 Year | -4.5%-14.4% | -27.2%-33.2% | 12.7%-6.0% |
Price Volatility Vs. Market
How volatile is Shanghai Pharmaceuticals Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Shanghai Pharmaceuticals Holding undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2607 (HK$14.68) is trading below our estimate of fair value (HK$63.66)
Significantly Below Fair Value: 2607 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2607 is good value based on its PE Ratio (14.4x) compared to the Healthcare industry average (16x).
PE vs Market: 2607 is poor value based on its PE Ratio (14.4x) compared to the Hong Kong market (9.9x).
Price to Earnings Growth Ratio
PEG Ratio: 2607 is poor value based on its PEG Ratio (1.5x)
Price to Book Ratio
PB vs Industry: 2607 is good value based on its PB Ratio (1.4x) compared to the HK Healthcare industry average (1.5x).
Next Steps
Future Growth
How is Shanghai Pharmaceuticals Holding forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
9.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2607's forecast earnings growth (9.6% per year) is above the savings rate (1.6%).
Earnings vs Market: 2607's earnings (9.6% per year) are forecast to grow slower than the Hong Kong market (11.7% per year).
High Growth Earnings: 2607's earnings are forecast to grow, but not significantly.
Revenue vs Market: 2607's revenue (13% per year) is forecast to grow faster than the Hong Kong market (9.7% per year).
High Growth Revenue: 2607's revenue (13% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2607's Return on Equity is forecast to be low in 3 years time (11.9%).
Next Steps
Past Performance
How has Shanghai Pharmaceuticals Holding performed over the past 5 years?
9.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2607 has high quality earnings.
Growing Profit Margin: 2607's current net profit margins (2.1%) are lower than last year (2.8%).
Past Earnings Growth Analysis
Earnings Trend: 2607's earnings have grown by 9.6% per year over the past 5 years.
Accelerating Growth: 2607's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2607 had negative earnings growth (-7%) over the past year, making it difficult to compare to the Healthcare industry average (10.4%).
Return on Equity
High ROE: 2607's Return on Equity (9.3%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Shanghai Pharmaceuticals Holding's financial position?
Financial Position Analysis
Short Term Liabilities: 2607's short term assets (CN¥99.1B) exceed its short term liabilities (CN¥74.6B).
Long Term Liabilities: 2607's short term assets (CN¥99.1B) exceed its long term liabilities (CN¥12.3B).
Debt to Equity History and Analysis
Debt Level: 2607's debt to equity ratio (61.2%) is considered high.
Reducing Debt: 2607's debt to equity ratio has increased from 24.8% to 61.2% over the past 5 years.
Debt Coverage: 2607's debt is not well covered by operating cash flow (14.5%).
Interest Coverage: 2607's interest payments on its debt are well covered by EBIT (18.9x coverage).
Balance Sheet
Inventory Level: 2607 has a high level of physical assets or inventory.
Debt Coverage by Assets: 2607's debt is covered by short term assets (assets are 3.3x debt).
Next Steps
Dividend
What is Shanghai Pharmaceuticals Holding's current dividend yield, its reliability and sustainability?
2.07%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: 2607's dividend (2.07%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.32%).
High Dividend: 2607's dividend (2.07%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.41%).
Stability and Growth of Payments
Stable Dividend: 2607's dividends per share have been stable in the past 10 years.
Growing Dividend: 2607's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (29.8%), 2607's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 2607's dividends in 3 years are forecast to be well covered by earnings (31.1% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.0yrs
Average management tenure
CEO
Man Cho (58yo)
6.7yrs
Tenure
CN¥3,973,000
Compensation
Mr. Man Cho has been the President of Shanghai Pharmaceuticals Holding Co., Ltd. since June 5, 2013 and serves as its Executive Director. Mr. Cho is a Director of Oncternal Therapeutics, Inc. since Decembe ...
CEO Compensation Analysis
Compensation vs Market: Man's total compensation ($USD566.37K) is about average for companies of similar size in the Hong Kong market ($USD577.68K).
Compensation vs Earnings: Man's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Executive Director | 6.7yrs | CN¥3.97m | 0.00070% CN¥391.3k | |
| CFO, VP | 6.7yrs | CN¥3.49m | 0.0025% CN¥1.4m | |
| VP & Executive Director | 6.7yrs | CN¥3.94m | no data | |
| Joint Company Secretary | 1.3yrs | no data | no data | |
| Secretary of Board & Joint Company Secretary | 0.5yrs | no data | no data | |
| General Manager | 0yrs | CN¥754.00k | no data |
4.0yrs
Average Tenure
47.5yo
Average Age
Experienced Management: 2607's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Executive Director | 6.7yrs | CN¥3.97m | 0.00070% CN¥391.3k | |
| CFO, VP | 6.7yrs | CN¥3.49m | 0.0025% CN¥1.4m | |
| VP & Executive Director | 6.7yrs | CN¥3.94m | no data | |
| Chairman of the Board | 6.7yrs | no data | no data | |
| Independent Non-Executive Director | 6.7yrs | CN¥200.00k | no data | |
| Chief Supervisor | 3.7yrs | no data | no data | |
| Independent Non-Executive Director | 6.7yrs | CN¥230.00k | no data | |
| Non-Executive Director | 6.7yrs | no data | no data | |
| Non-Executive Vice Chairman | 0.7yrs | no data | no data | |
| Independent Non-Executive Director | 0yrs | no data | no data |
6.7yrs
Average Tenure
51.5yo
Average Age
Experienced Board: 2607's board of directors are considered experienced (6.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Shanghai Pharmaceuticals Holding Co., Ltd's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Shanghai Pharmaceuticals Holding Co., Ltd
- Ticker: 2607
- Exchange: SEHK
- Founded: 1994
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: CN¥50.328b
- Listing Market Cap: CN¥55.898b
- Shares outstanding: 2.84b
- Website: https://www.sphchina.com
Number of Employees
Location
- Shanghai Pharmaceuticals Holding Co., Ltd
- Shanghai Pharmaceutical Building
- No.200 Taicang Road
- Shanghai
- 200020
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 601607 | SHSE (Shanghai Stock Exchange) | Yes | Domestic Shares | CN | CNY | Jul 1996 |
| 601607 | XSSC (Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect) | Yes | Domestic Shares | CN | CNY | Jul 1996 |
| 2607 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Foreign Shares-Foreign Listed | HK | HKD | May 2011 | |
| SHPM.F | OTCPK (Pink Sheets LLC) | Foreign Shares-Foreign Listed | US | USD | May 2011 | |
| S1R | DB (Deutsche Boerse AG) | Foreign Shares-Foreign Listed | DE | EUR | May 2011 | |
| 2607 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Foreign Shares-Foreign Listed | HK | HKD | May 2011 | |
| 2607 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Foreign Shares-Foreign Listed | HK | HKD | May 2011 | |
| SHPM.Y | OTCPK (Pink Sheets LLC) | ADR REPS SHS H | US | USD | Mar 2013 |
Biography
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People’s Republic of China. It operates through Production, Distribution, Retail, and Others segments. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestion and immune system, cardiovascular, anti-infection, nervous system and mental disorder, and oncology. It provides approximately 700 varieties of drugs and 20 dosage forms. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it operates a network of retail pharmacy stores, as well as engages in consulting service, assets management, investment holding operations, etc. Further, the company manufactures and trades in medicines, and medical equipment and instruments. It operates approximately 2,000 chained pharmacies in 16 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/26 13:07 |
| End of Day Share Price | 2020/02/26 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.